1 week Ago By ABMN Staff
Trexquant Investment LP purchased a new stake in Abeona Therapeutics Inc ( NASDAQ:ABEO – Free Report ) in the 4th quarter, HoldingsChannel reports. The firm purchased 68,516 shares of the biopharmaceutical company’s stock, valued at approximately $382,000. A number of other large investors also recently bought and sold shares of the business.
Jane Street Group LLC acquired a new stake in Abeona Therapeutics in the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the 3rd quarter worth approximately $151,000.
XTX Topco Ltd purchased a new position in shares of Abeona Therapeutics during the 3rd quarter valued at approximately $160,000. JPMorgan Chase & Co. grew its stake in Abeona Therapeutics by 74.
2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares during the period.
Finally, Wellington Management Group LLP purchased a new stake in Abeona Therapeutics in the 4th quarter worth $520,000. Institutional investors and hedge funds own 80.56% of the company’s stock.
Insider Buying and Selling In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.
00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at $6,478,439.16.
This trade represents a 1.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink .
Over the last 90 days, insiders have sold 33,000 shares of company stock worth $161,420. 5.40% of the stock is owned by corporate insiders.
Analyst Ratings Changes View Our Latest Stock Analysis on ABEO Abeona Therapeutics Price Performance Shares of NASDAQ ABEO opened at $4.60 on Monday. The stock has a market capitalization of $223.
26 million, a price-to-earnings ratio of -1.71 and a beta of 1.71.
Abeona Therapeutics Inc has a 52 week low of $3.05 and a 52 week high of $8.45.
The firm has a 50-day simple moving average of $5.21 and a 200-day simple moving average of $5.71.
The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.
31. Abeona Therapeutics ( NASDAQ:ABEO – Get Free Report ) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.
24) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.
On average, equities analysts predict that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year. Abeona Therapeutics Profile ( Free Report ) Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases.
The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. Further Reading Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc ( NASDAQ:ABEO – Free Report ).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
